Triumvira Immunologics
Michael V. Seiden, M.D., PhD, is an oncologist and healthcare executive with 30 years of experience spanning a variety of clinical, research, and operational roles. He currently serves as an advisor or Board member for a variety of small to mid-size early-stage companies mostly centered around cancer and specialty care. He is currently a Board Member for Glide Health, Medicom Technologies, and Nemucore Medical Innovations and advises several oncology companies including Grail, EQRX, Blue Note Therapeutics, and other venture back companies Previous Board roles have included Next Oncology and Medfusion prior to its sale to Quest. He also serves as a Board Member for non-profit organizations including the Damon Runyon Cancer Research Foundation and Lisa’s Army.
His previous operational roles include serving as the President of The US Oncology Network, the largest collection of community-based oncology care practices in the US, and a leader in the delivery of value-based oncology care and community-based clinical research. Previously, Dr. Seiden served as the senior vice president and Chief Medical Officer of The US Oncology Network and McKesson Specialty Health. Before joining The Network, he served as CEO, President, and Cancer Center Director of Fox Chase Cancer Center, a National Cancer Institute-designated Comprehensive Cancer Center, research facility, and hospital in Philadelphia. Prior to Fox Chase, Dr. Seiden spent many years practicing oncology at Massachusetts General Hospital and Harvard Medical School, where he also served as Chief of the Cancer Center Clinical Research Unit as well as the program director for the Gynecologic Oncology Research Program for the Dana Farber/Harvard Cancer Center.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Triumvira Immunologics
1 followers
At Triumvira Immunologics, Inc., our team is dedicated to a vision of finding a cure and providing new hope for patients with life-threatening disease. Co-founded in 2015 by licensing technology out of McMaster University and Bloom Burton & Co., Triumvira is working to achieve this vision by developing a proprietary T cell Antigen Coupler (TAC) technology, thought to be safer and more efficacious than current cancer treatments including chimeric antigen receptor (CAR) and engineered T cell receptor (TCR) therapies. We are an emergent US company with operations in the United States and Canada. We bring together talent from a wide range of disciplines including immunobiology, drug development, fundraising, commercialization and finance, with decades of experience across big pharma and small biotech, multiple industries and academia. We are passionate about science that pushes the limits, the patients that drive the heart of our work, and the wellness of our employees. We embrace flexibility. If you are looking for a career where you are encouraged to be innovative, challenge the status quo, and have some fun while doing it, Triumvira is the place for you.